Table 1.
Characteristics and methodological quality of included studies.
| Study ID | Sample | Diagnosis standard |
Intervention | Control | Course (week) | Outcome measure |
|---|---|---|---|---|---|---|
| Zheng, 2011 [40] | 60 | CGMH-2005 | Modified BBTD (600 mL/d#) | Enalapril (10 mg qd) | 3 | BP; adverse effect |
| Xiong, 2010 [41] | 60 | CGMH-2005; GCRNDTCM | Modified BBTD (250 mL/d#) plus L-amlodipine (2.5 mg qd) | L-amlodipine (2.5 mg qd) | 4 | BP |
| Chen et al., 2005 [42] | 70 | Hypertension diagnostic criteria (unclear); CDTDSS | Modified BBTD (240 mL/d#) plus nitrendipine (no detailed information) | Nitrendipine (no detailed information) | 8 | BP |
| Wang, 2001 [43] | 100 | 1999 WHO-ISH GMH | Modified BBTD (1 dose/d#) plus captopril (25–37.5 mg tid) | Captopril (25–37.5 mg tid) | 4 | BP |
| Che et al., 2011 [44] | 60 | 1999 WHO-ISH GMH; TCM diagnostic criteria (unclear) | Modified BBTD (400 mL/d#) plus nifedipine controlled release tablet (10 mg bid) | Nifedipine controlled release tablet (10 mg bid) | 4 | BP; adverse effect |
| Jin, 2011 [45] | 60 | CGMH-2005; GCRNDTCM | BBTD plus antihypertensive drugs (400 mL/d#) | Antihypertensive drugs (no detailed information) | 6 | BP; adverse effect |
| Chen, 2007 [46] | 120 | CGPMHBP-2004; GCRNDTCM | Modified BBTD (1 dose/d#) plus losartan (50 mg qd) | Losartan (50 mg qd) | 12 | BP |
| Guo, 2009 [47] | 94 | CGPMHBP-2004; CIM | Modified BBTD (400–500 mL/d#) plus compound reserpine-triamterene tablets (1 pill, qd) | Compound reserpine-triamterene tablets (1 pill, qd) | 4 | BP |
| Li, 2011 [48] | 139 | Hypertension and TCM diagnostic criteria (unclear) | Modified BBTD (450 mL/d#) plus felodipine sustained release tablets (1 pill, bid)/levamlodipine besylate tablets (1 pill, qd) | Felodipine sustained release tablets (1 pill, bid)/levamlodipine besylate tablets (1 pill, qd) | 12 | BP |
| Guo et al., 2006 [49] | 116 | 1999 WHO—ISH GMH; GCRNDTCM | Modified BBTD (250 mL/d#) plus levamlodipine besylate tablets (5 mg qd) | Levamlodipine besylate tablets (5 mg qd) | 2 | BP |
| Zhou, 2008 [50] | 102 | CGMH-2005; GCRNDTCM | Modified BBTD (400 mL/d#) plus nifedipine sustained release tablets (10 mg bid) | Nifedipine sustained release tablets (10 mg bid) | 4 | BP; adverse effect |
| Wu et al., 2007 [51] | 87 | CGMH-1999; GCRNDTCM | Modified BBTD (1 dose/d#) plus antihypertensive drugs (no detailed information) | Antihypertensive drugs (no detailed information) | 8 | BP |
| Lei and Lin, 2009 [52] | 114 | CGMH-2005; GCRNDTCM | BBTD (400 mL/d#) plus benazepril (10 mg qd) | Benazeprill (10 mg qd) | 4 | BP |
| Liu et al., 2007 [53] | 80 | 1999 WHO—ISH GMH; GCRNDTCM | Modified BBTD (300 mL/d#) | Captopril (12.5 mg bid) | 4 | BP |
| Zhang, 2002 [54] | 80 | JNC-VI | Modified BBTD (1 dose/d#) plus felodipine (5 mg qd)/hydrochlorothiazide (12.5 mg bid) | Felodipine (5 mg qd)/hydrochlorothiazide (12.5 mg bid) | 1 | BP |
| Wang, 2005 [55] | 82 | 1999 WHO—ISH GMH; GCRNDTCM | Modified BBTD (1 dose/d#) plus captopril (no detailed information) | Captopril (no detailed information) | 4 | BP |